ClinicalTrials.gg
Active, not recruitingNCT07148414SKYWAY-RDUpdated Jun 5, 2026

A Study of SPY072 in Rheumatic Disease

A Phase 2 interventional study of SPY002-072 and Placebo in Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis, sponsored by Spyre Therapeutics, Inc.. Active, not recruiting at 64 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Spyre Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 122 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Planned enrollment
225th of 771
285 · median 120
Started
2025
with 30 others
Phase 2
215 of 975
12 open now
Primary completion
2026-10
later than 25 of 121 live
Registered
945th of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 225th largest by planned enrollment of the 771 interventional ones that give a count, is one of 31 that started in 2025, is one of 215 in phase 2, reaches primary completion later than 25 of the 121 other live ones, and was the 945th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease (RD).

Read the detailed description

The basket study comprises of substudies in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatric arthritis (PsA) as follows:

  • RA substudy: Moderately to severely active RA despite treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic disease modifying anti-rheumatic drugs (bDMARDs), or targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs)
  • axSpA substudy: Moderately to severely active axSpA despite treatment with non-steroidal anti-inflammatory drugs (NSAIDS), bDMARDs, or tsDMARDs
  • PsA substudy: Moderately to severely active PsA despite treatment with NSAIDs, csDMARDs, bDMARDs, or tsDMARDs
03

Conditions studied

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Axial Spondyloarthritis
  • Rheumatic Diseases
  • Rheumatic Joint Disease
  • PsA (Psoriatic Arthritis)
  • AxSpA
  • Rheumatologic Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For rheumatoid arthritis:

  • Moderate-to-severely active RA as defined by the presence of ≥4 swollen joints (based on 28 joint count) and ≥4 tender joints (based on 28 joint count) at Screening and Day 1.
  • Documentation of ≥1 of the following:

    1. Positive test results for rheumatoid factor or anti-citrullinated peptide antibodies at Screening, OR
    2. Radiology report documenting bony erosions in hands or feet consistent with RA on previous radiographs
  • Inadequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to:

    1. ≥1 csDMARD treatment; AND/OR
    2. ≤2 classes of bDMARD/tsDMARD treatment (>2 classes of bDMARDs and/or tsDMARDs is exclusionary)

For axial spondyloarthritis:

  • Moderate-to-severely active axSpA defined by BOTH of the following at Screening AND Day 1:

    1. BASDAI ≥4, AND
    2. Back pain ≥4 (from BASDAI Item 2)
  • hsCRP greater than the per the central laboratory at Screening
  • Inadequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to:

    1. 2 different NSAIDs given at the maximum tolerated dose for ≥4 weeks or intolerant to or has a to NSAID therapy; AND/OR
    2. ≤2 classes of bDMARD (anti-TNF or anti-IL-17)/tsDMARD at an approved dose for ≥12 weeks (>2 classes of bDMARDs/tsDMARDs is exclusionary)

For psoriatic arthritis:

  • Screening and Day 1 TJC ≥3 out of 68 and SJC ≥3 out of 66 (dactylitis counts as 1 joint each)
  • ≥1 active plaque psoriasis lesion and/or a documented history of psoriasis
  • Inadequate response (defined as signs and symptoms of persistently active disease, loss of response, or intolerance) to:

    1. ≥1 NSAID treatment; AND
    2. ≥1 csDMARD treatment; AND/OR ≤2 classes of bDMARD/tsDMARD treatment (>2 classes of bDMARDs and/or tsDMARDs is exclusionary)

Exclusion criteria

Exclusion Criteria:

  • Inadequate response to >2 classes of bDMARDs/tsDMARDs
  • Other , rheumatologic, inflammatory diseases or pain-amplification syndromes that might confound the evaluations of efficacy of SPY072
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
285 participants (estimated)

Study arms

  • Experimental
    Rheumatoid Arthritis, Dose Regimen 1

    Participants will receive double-blind dosing regimen 1 of SPY072

    Drug: SPY002-072

  • Experimental
    Rheumatoid Arthritis, Dose Regimen 2

    Participants will receive double-blind dosing regimen 2 of SPY072

    Drug: SPY002-072

  • Experimental
    Psoriatic Arthritis

    Participants will receive double-blind dose of SPY072

    Drug: SPY002-072

  • Experimental
    Axial Spondyloarthritis

    Participants will receive double-blind dose of SPY072

    Drug: SPY002-072

  • Placebo comparator
    Rhematoid Arthritis Placebo

    Participants will receive matching placebo

    Drug: Placebo

  • Placebo comparator
    Psoriatic Arthritis Placebo

    Participants will receive matching placebo

    Drug: Placebo

  • Placebo comparator
    Axial Spondyloarthritis Placebo

    Participants will receive matching placebo

    Drug: Placebo

Interventions

  • DrugSPY002-072

    Experimental

    Also known as: SPY072

  • DrugPlacebo

    Matching Placebo

06

What researchers measure

Primary outcomes

  1. Rheumatoid Arthritis: Change from baseline in Disease Activity Score in 28 joints (c-reactive protein) (DAS-CRP)

    The score is calculated based on the number of tender and swollen joints out of 28 assessed (TJC28 and SJC28), a measure of inflammation in the blood (c-reactive protein, CRP), and the subject's overall assessment of their health (patient global assessment). Scores range from 0-10. Higher scores indicate greater disease activity.

    Time frame: Week 12

  2. Axial Spondyloarthritis: Change from baseline in Ankylosing Spondylitis Disease Activity Score (ADAS)

    The score combines 5 disease activity variables (back pain, duration of morning stiffness, patient global assessment of disease activity, peripheral pain/swelling and measure of inflammation) to measure disease activity. Lowest score is 0.6 and increases as disease worsens. Higher scores indicate greater disease activity.

    Time frame: Week 16

  3. Psoriatic Arthritis: Proportion of participants who achieve an American College of Rheumatology 20 Response Criteria (ACR20) response

    The proportion of subjects who achieve at least 20% improvement in tender and swollen joint counts (TJC and SJC), and at least 20% improvement in 3 out of 5 other disease activity measures (patient global assessment, physician global assessment, patient pain assessment, health assessment questionnaire, and measure of inflammation) will be assessed.

    Time frame: Week 16

Secondary outcomes

  1. Rheumatoid Arthritis: Proportion of participants who achieve an ACR20 response

    The proportion of subjects who achieve at least 20% improvement in tender and swollen joint counts, and at least 20% improvement in 3 out of 5 other disease activity measures will be assessed.

    Time frame: Week 12

  2. Axial Spondyloarthritis: Proportion of participants who achieve an Assessment of Spondyloarthritis International Society (40% improvement) (ASAS40) response

    The proportion of subjects who achieve at least 40% improvement in at least 3 out of 4 key domains related to disease severity (patient global assessment of disease activity, back pain, physical function, inflammation) while not experiencing worsening in the remain domain will be assessed.

    Time frame: Week 16

  3. Psoriatic Arthritis: Change from baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA)

    The sum of 5 key disease variables (tender joint count, swollen joint count, patient pain assessment, patient global assessment of disease activity, and C-reactive protein) will be assessed. Scores range from 0.1 to 86. Higher score indicates higher disease activity.

    Time frame: Week 16

07

Study locations

64 sites
  • Site 113
    Avondale, Arizona 85392, United States
  • Site 118
    Tucson, Arizona 85748, United States
  • Site 114
    Chula Vista, California 91910, United States
  • Site 111
    Covina, California 91722, United States
  • Site 108
    Tujunga, California 91042, United States
  • Site 112
    Upland, California 91786, United States
  • Site 107
    Whittier, California 90602, United States
  • Site 115
    Aventura, Florida 33180, United States
  • Site 109
    Hialeah, Florida 33016, United States
  • Site 106
    Ormond Beach, Florida 32174, United States
  • Site 110
    Tampa, Florida 33614, United States
  • Site 116
    Willowbrook, Illinois 60527, United States
  • Site 119
    Rockville, Maryland 20850, United States
  • Site 104
    Duncansville, Pennsylvania 16635, United States
  • Site 105
    Corpus Christi, Texas 78404, United States
  • Site 120
    Irving, Texas 75039, United States
  • Site 103
    Tomball, Texas 77375, United States
  • Site 102
    Tomball, Texas 77377, United States
  • Site 503
    Lovech, Lovech 5500, Bulgaria
  • Site 502
    Pleven, Pleven 5803, Bulgaria
  • Site 506
    Plovdiv, Plovdiv 4000, Bulgaria
  • Site 505
    Plovdiv, Plovdiv 4003, Bulgaria
  • Site 504
    Varna, Varna 9000, Bulgaria
  • Site 706
    Hlučín, Hlučín 748 01, Czechia
  • Site 702
    Moravská Ostrava, Ostrava-město 702 00, Czechia
  • Site 704
    Pardubice, Pardubice Region 530 02, Czechia
  • Site 705
    Prague, Praha, Hlavní Mesto 130 00, Czechia
  • Site 703
    Prague, Praha, Hlavní Mesto 140 00, Czechia
  • Site 701
    Uherské Hradiště, Zlín 68601, Czechia
  • Site 303
    Tbilisi, K'alak'i T'bilisi 0102, Georgia
  • Site 304
    Tbilisi, K'alak'i T'bilisi 0112, Georgia
  • Site 301
    Tbilisi, K'alak'i T'bilisi 0159, Georgia
  • Site 307
    Tbilisi, K'alak'i T'bilisi 0172, Georgia
  • Site 305
    Tbilisi, K'alak'i T'bilisi 0186, Georgia
  • Site 308
    Batumi, 6010, Georgia
  • Site 302
    Kutaisi, 4600, Georgia
  • Site 306
    Tbilisi, 0186, Georgia
  • Site 201
    Chisinau, MD-2025, Moldova
  • Site 202
    Chisinau, MD-2025, Moldova
  • Site 401
    Krakow, Lesser Poland Voivodeship 30-363, Poland
  • Site 407
    Nowa Sól, Lubusz Voivodeship 67-100, Poland
  • Site 404
    Lodz, Lódzkie 91-363, Poland
  • Site 403
    Warsaw, Masovian Voivodeship 02-677, Poland
  • Site 402
    Opole, Opole Voivodeship 45-819, Poland
  • Site 406
    Gdynia, Pomeranian Voivodeship 81-384, Poland
  • Site 405
    Warszawa, Pomeranian Voivodeship 00-874, Poland
  • Site 408
    Elblag, Warmian-Masurian Voivodeship 82-300, Poland
  • Site 602
    A Coruña, A Coruña 15006, Spain
  • Site 604
    Chiclana de la Frontera, Cadiz 11139, Spain
  • Site 601
    Santander, Madrid 39008, Spain
  • Site 603
    Seville, Sevilla 41010, Spain
  • Site 809
    Chernihiv, Chernihiv Oblast 14029, Ukraine
  • Site 813
    Kyiv, Kyiv Oblast 02091, Ukraine
  • Site 806
    Kyiv, Kyiv Oblast 03049, Ukraine
  • Site 804
    Kyiv, Kyiv Oblast 04050, Ukraine
  • Site 803
    Kyiv, Kyiv Oblast 2125, Ukraine
  • Site 805
    Kyiv, Kyiv Oblast 4106, Ukraine
  • Site 807
    Lviv, Lviv Oblast 79044, Ukraine
  • Site 808
    Ternopil, Ternopil Oblast 46002, Ukraine
  • Site 810
    Ternopil, Ternopil Oblast 46002, Ukraine
  • Site 801
    Vinnytsia, Vinnytsia Oblast 21028, Ukraine
  • Site 802
    Vinnytsia, Vinnytsia Oblast 21029, Ukraine
  • Site 812
    Vinnytsia, Vinnytska 21000, Ukraine
  • Site 811
    Zhytomyr, Zhytomyr Oblast 10002, Ukraine
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Oct 2026, 14 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 14 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2025
First posted
Aug 29, 2025
StartActual
Aug 21, 2025
Primary completionEst.
Oct 31, 2026
CompletionEst.
Mar 31, 2028
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07148414
Lead sponsor
Spyre Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 29, 2025
Start date
Aug 21, 2025
Primary completion
Oct 31, 2026 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Jun 5, 2026

Study contacts

SKYWAY-RD Study Director
study director · Spyre Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion